OBJECTIVE
Cenobamate is approved for treatment of focal seizures in adults, but evidence on non-seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal-onsEt SeizureS (BLESS) study evaluated patient- and clinician-reported outcomes for up to 52 weeks of cenobamate trea...
Simona Lattanzi, G. d'Orsi, M. T. Di Claudio et al.· Epilepsia· 0 citations
Continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is an emerging treatment for advanced Parkinson's disease (PD). We report atypical psychosis with Ekbom-like somatic hallucinations during CSFLI. A 74-year-old man with a 16-year history of PD (Hoehn and Yahr stage 3), mild cognitive impairment (Montreal...
Mario Meloni, Fabrizio De Ascaniis, Gianni Orofino et al.· Clinical Psychopharmacology...· 0 citations
Data-driven analyses suggest three distinct cognitive profiles within MCI-RBD, with executive-attentional dysfunction emerging as a prominent feature and potentially representing a key target for cognitive evaluation and risk stratification.
Martina Mulas, F. Meloni, M. Figorilli et al.· Sleep Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.